Inmune Bio Inc. company information, Employees & Contact Information

INmune Bio (NASDAQ: INMB) schedules results call for 4:30 PM ET on Oct 30 Stock Titan

INmune Bio to Participate in Dermatologic Rare Disease Panel at the Maxim Growth Summit 2025 Yahoo Finance

INmune Bio Inc. to Report Third Quarter 2025 Financial Results and Provide a Corporate Update on Thursday, October 30, 2025 The Manila Times

INmune Bio, Inc. Collaborates on Study Showing XPro™ Treatment Reduces Alzheimer’s-like Pathology After Traumatic Brain Injury in Mice Nasdaq

INmune Bio Announces Submission of Phase 2 MINDFuL Trial Results in Alzheimer’s Disease to npj Dementia, a Nature Portfolio Journal Yahoo Finance

Oct 22 CEO Panel: INmune Bio's CORDStrom for RDEB — David Moss at Maxim Growth Summit in NYC Stock Titan

INmune Bio Inc. to Host Conference Call on Phase 2 MINDFuL Trial Results for Early Alzheimer's Disease Nasdaq

INmune Bio, Inc. Announces Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Yahoo Finance

Clinical-Stage Biotech INmune Bio Secures $19M Through Strategic Share Offering Stock Titan

INmune Bio Announces Successful Completion of First Commercial Pilot-Scale Manufacturing Run of CORDStrom™ at CGT Catapult Yahoo Finance

Clinical-Stage Immunology Company INmune Bio Secures $19M from Healthcare Investors at Market Price Stock Titan

INmune Bio, Inc. Announces Closing of Approximately $19 Million Registered Direct Offering Priced At-the-Market Under Nasdaq Rules Yahoo Finance

INmune Bio to Publish Video Detailing MINDFuL Trial Findings of XPro™ Presented at the Alzheimer’s Association International Conference Yahoo Finance

INmune Bio's Novel NK Cell Therapy Shows Tumor Reduction in Advanced Prostate Cancer Trial Stock Titan

INmune Bio Inc. Announces First Quarter 2025 Results and Provides Business Update Yahoo Finance

Breakthrough: New Alzheimer's Drug XPro Shows Promise in Key Patient Group, Zero ARIA Cases Stock Titan

INmune Bio to Present Phase 2 MINDFuL Trial Findings of XPro™ at the Alzheimer’s Association International Conference Yahoo Finance

INmune Bio Reports Key Findings from Phase 2 MINDFuL Trial of XPro™ in Early Alzheimer’s Disease Yahoo Finance

INmune Bio’s CaRe PC Trial of INKmune™ in Metastatic Castration-Resistant Prostate Cancer Meets Endpoints and Is Closed to Enrollment Yahoo Finance

Breakthrough in Alzheimer's Treatment: Phase 2 Trial Reveals XPro Drug's Impact on Cognitive Decline Stock Titan

OmniScience Inc. and INmune Bio Inc. Partner to Accelerate a Phase 2 Alzheimer’s Trial with Vivo, a Novel genAI Clinical Trial Control Tower Business Wire

INmune Bio Inc. Reports Q2 2025 Financial Results and Business Updates Quiver Quantitative

First Patient Dosed With INKmune Therapy in Phase 1/2 Trial for mCRPC Targeted Oncology

INmune Bio Inc. to Host Conference Call on August 7, 2025 for Q2 Results and Corporate Update Quiver Quantitative

INmune Bio to Present Q2 2025 Financial Results and Key Clinical-Stage Updates on August 7 Stock Titan

Cortical microstructural MRI for detection of early target engagement in AD drug trials: post-hoc analysis of exploratory outcomes from a Phase 1b safety study for XPro1595 in AD Wiley

Breakthrough in Rare Disease Treatment: INmune Bio Successfully Manufactures RDEB Cell Therapy at UK Facility Stock Titan

INmune Bio Inc. Achieves Key Patent Milestone for CORDStrom™ Cell Therapy Platform Nasdaq

Zero ARIA Side Effects: INmune Bio's Alzheimer's Drug Shows Safety Edge Over Amyloid Therapies Stock Titan

INmune Bio: Finding Pay Dirt In Alzheimer's? (NASDAQ:INMB) Seeking Alpha

INmune Bio's Triple Threat: Alzheimer's Trial Fully Enrolled, FDA Designations Secured Stock Titan

INmune Bio Inc. Reports Safe Phase 1 Results for INKmune™ in mCRPC, Opens Phase 2 Enrollment Nasdaq

Promising Patient Profile Emerges in Major Alzheimer's Drug Trial: 69% Carry Key Risk Gene Stock Titan

Breakthrough: New Drug Reduces Alzheimer's Risk After Brain Injury, DoD-Backed Study Shows Stock Titan

Using the Innate Immune System to Treat Disease Fierce Biotech

INmune Bio Inc. to Introduce NeuLiv™ Program for Treatment GlobeNewswire

INmune Bio Reports Positive Preliminary Data from INB03 Phase I Clinical Trial in Cancer GlobeNewswire